Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies

Jennifer D. Stone, David M Kranz

Research output: Contribution to journalReview article

Abstract

Over the last several years, there has been considerable progress in the treatment of cancer using gene modified adoptive T cell therapies. Two approaches have been used, one involving the introduction of a conventional αβ T cell receptor (TCR) against a pepMHC cancer antigen, and the second involving introduction of a chimeric antigen receptor (CAR) consisting of a single-chain antibody as an Fvfragment linked to transmembrane and signaling domains. In this review, we focus on one aspect of TCR-mediated adoptive T cell therapies, the impact of the affinity of the aß TCR for the pepMHC cancer antigen on both efficacy and specificity. We discuss the advantages of higher-affinity TCRs in mediating potent activity of CD4 T cells. This is balanced with the potential disadvantage of higher-affinity TCRs in mediating greater self-reactivity against a wider range of structurally similar antigenic peptides, especially in synergy with the CD8 co-receptor. Both TCR affinity and target selection will influence potential safety issues. We suggest pre-clinical strategies that might be used to examine each TCR for possible on-target and off-target side effects due to self-reactivities, and to adjust TCR affinities accordingly.

Original languageEnglish (US)
Article numberArticle 244
JournalFrontiers in immunology
Volume4
Issue numberAUG
DOIs
StatePublished - Sep 16 2013

Fingerprint

Cell- and Tissue-Based Therapy
T-Cell Antigen Receptor
T-Lymphocytes
Antigens
Single-Chain Antibodies
Antigen Receptors
Second Primary Neoplasms
Neoplasm Genes
Safety
Peptides
Neoplasms

Keywords

  • Adoptive T cell therapy
  • T cell cross-reactivity
  • T cell sensitivity
  • TCR affinity
  • Tumor-associated epitopes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies. / Stone, Jennifer D.; Kranz, David M.

In: Frontiers in immunology, Vol. 4, No. AUG, Article 244, 16.09.2013.

Research output: Contribution to journalReview article

@article{94d3ce89857d463d8dfab1df4d0c1e56,
title = "Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies",
abstract = "Over the last several years, there has been considerable progress in the treatment of cancer using gene modified adoptive T cell therapies. Two approaches have been used, one involving the introduction of a conventional αβ T cell receptor (TCR) against a pepMHC cancer antigen, and the second involving introduction of a chimeric antigen receptor (CAR) consisting of a single-chain antibody as an Fvfragment linked to transmembrane and signaling domains. In this review, we focus on one aspect of TCR-mediated adoptive T cell therapies, the impact of the affinity of the a{\ss} TCR for the pepMHC cancer antigen on both efficacy and specificity. We discuss the advantages of higher-affinity TCRs in mediating potent activity of CD4 T cells. This is balanced with the potential disadvantage of higher-affinity TCRs in mediating greater self-reactivity against a wider range of structurally similar antigenic peptides, especially in synergy with the CD8 co-receptor. Both TCR affinity and target selection will influence potential safety issues. We suggest pre-clinical strategies that might be used to examine each TCR for possible on-target and off-target side effects due to self-reactivities, and to adjust TCR affinities accordingly.",
keywords = "Adoptive T cell therapy, T cell cross-reactivity, T cell sensitivity, TCR affinity, Tumor-associated epitopes",
author = "Stone, {Jennifer D.} and Kranz, {David M}",
year = "2013",
month = "9",
day = "16",
doi = "10.3389/fimmu.2013.00244",
language = "English (US)",
volume = "4",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",
number = "AUG",

}

TY - JOUR

T1 - Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies

AU - Stone, Jennifer D.

AU - Kranz, David M

PY - 2013/9/16

Y1 - 2013/9/16

N2 - Over the last several years, there has been considerable progress in the treatment of cancer using gene modified adoptive T cell therapies. Two approaches have been used, one involving the introduction of a conventional αβ T cell receptor (TCR) against a pepMHC cancer antigen, and the second involving introduction of a chimeric antigen receptor (CAR) consisting of a single-chain antibody as an Fvfragment linked to transmembrane and signaling domains. In this review, we focus on one aspect of TCR-mediated adoptive T cell therapies, the impact of the affinity of the aß TCR for the pepMHC cancer antigen on both efficacy and specificity. We discuss the advantages of higher-affinity TCRs in mediating potent activity of CD4 T cells. This is balanced with the potential disadvantage of higher-affinity TCRs in mediating greater self-reactivity against a wider range of structurally similar antigenic peptides, especially in synergy with the CD8 co-receptor. Both TCR affinity and target selection will influence potential safety issues. We suggest pre-clinical strategies that might be used to examine each TCR for possible on-target and off-target side effects due to self-reactivities, and to adjust TCR affinities accordingly.

AB - Over the last several years, there has been considerable progress in the treatment of cancer using gene modified adoptive T cell therapies. Two approaches have been used, one involving the introduction of a conventional αβ T cell receptor (TCR) against a pepMHC cancer antigen, and the second involving introduction of a chimeric antigen receptor (CAR) consisting of a single-chain antibody as an Fvfragment linked to transmembrane and signaling domains. In this review, we focus on one aspect of TCR-mediated adoptive T cell therapies, the impact of the affinity of the aß TCR for the pepMHC cancer antigen on both efficacy and specificity. We discuss the advantages of higher-affinity TCRs in mediating potent activity of CD4 T cells. This is balanced with the potential disadvantage of higher-affinity TCRs in mediating greater self-reactivity against a wider range of structurally similar antigenic peptides, especially in synergy with the CD8 co-receptor. Both TCR affinity and target selection will influence potential safety issues. We suggest pre-clinical strategies that might be used to examine each TCR for possible on-target and off-target side effects due to self-reactivities, and to adjust TCR affinities accordingly.

KW - Adoptive T cell therapy

KW - T cell cross-reactivity

KW - T cell sensitivity

KW - TCR affinity

KW - Tumor-associated epitopes

UR - http://www.scopus.com/inward/record.url?scp=84883705209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883705209&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2013.00244

DO - 10.3389/fimmu.2013.00244

M3 - Review article

C2 - 23970885

AN - SCOPUS:84883705209

VL - 4

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - AUG

M1 - Article 244

ER -